Protalix BioTherapeutics (PLX)

• Market cap: $176M
• 1 day: -1.65%
• 5 days: -10.49%
• 1 month: 2.58%
• 3 months: 43.98%
• 6 months: 146.42%
• Year to date: 21.32%
• 1 year: 68.31%
• 5 years: -38.24%
• 10 years: -88.05%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Employees: 208

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

880% more call options, than puts

Call options by funds: $98K | Put options by funds: $10K

135% more capital invested

Capital invested by funds: $3.52M [Q3] → $8.26M (+$4.75M) [Q4]

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

2% more funds holding

Funds holding: 44 [Q3] → 45 (+1) [Q4]

1.32% more ownership

Funds ownership: 4.65% [Q3] → 5.97% (+1.32%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 528% upside
• Avg. target: $15 528% upside
• High target: $15 528% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 126 / 333 met price target

528% upside $15

Buy Maintained

3 Feb 2025